🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Placebo Mannitol 100mg pfi, ACEPURIN, poeder voor infusievloeistof 1g/100 ml

    Disc Medicine

    Brain injury in neonates with critical congenital heart disease requiring cardiac surgery with cardiopulmonary bypass.

    phase 3 small molecule active

    1 trial

  2. Placebo Matching Mitapivat

    Agios Netherlands B.V.

    Non-Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  3. Placebo Matching Mitapivat

    Agios Netherlands B.V.

    Transfusion-dependent Alpha-Thalassemia

    phase 3 small molecule active

    1 trial

  4. Placebo Ocrelizumab, Paracetamol 500mg Tablets, Methylprednisolone 500 mg powder and solvent for solution for injection/infusion, Ocrevus 300 mg concentrate for solution for infusion, Ocrevus 300 mg concentrate for solution for infusion, Diphenhydramine Hydrochloride Tablets 50 mg

    Hoffmann-La Roche

    Primary Progressive Multiple Sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  5. Placebo Ocrevus, DIPHENHYDRAMINE HYDROCHLORIDE, METHYLPREDNISOLONE , METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Ocrevus 300 mg concentrate for solution for infusion, METHYLPREDNISOLONE SODIUM SUCCINATE, METHYLPREDNISOLONE SODIUM SUCCINATE, Dormutil N, Ocrevus 300 mg concentrate for solution for infusion

    Hoffmann-La Roche

    Primary progressive multiple sclerosis (PPMS)

    phase 3 small molecule active

    1 trial

  6. Placebo Trontinemab, Amyvid 800 MBq/mL solution for injection, VIZAMYL 400 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 1900 MBq/mL solution for injection, Amyvid 800 MBq/mL solution for injection, Neuraceq 300 MBq/mL solution for injection, Trontinemab, [18F]MK-6240

    Hoffmann-La Roche

    Early Symptomatic Alzheimer’s Disease (MCI to Mild Dementia Due to AD)

    phase 3 small molecule active

    1 trial

  7. Placebo cannabis oil. Components: cannabis granulated flos after (ethanol) extraction of cannabinoids; arachidis oleum raffinatum., TA-CBD 10

    Disc Medicine

    Refractory Epilepsy

    phase 3 small molecule active

    1 trial

  8. Placebo capsules for Doxycycline 200 mg (Empty Hpmc capsule, vcaps plus, swedish orange filled with microcrystalline cellulose), Doxycycline EG 100 mg tabletten

    The George Institute

    bacterial sexually transmitted infections

    phase 3 small molecule active

    1 trial

  9. Placebo contains excipients only and is visually indistinguishable from the Telitacicept, Telitacicept injection

    Vor Biopharma

    Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  10. Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  11. Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

  12. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  13. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  14. Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  15. Placebo for AMG 145, EVOLOCUMAB

    Amgen

    Adults at high risk of cardiovascular events without prior MI or stroke.

    phase 3 small molecule active

    1 trial

  16. Placebo for AMG 890

    Amgen

    Cardiovascular Disease

    phase 3 small molecule active

    1 trial

  17. Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 3 small molecule active

    1 trial

  18. Placebo for AZP-3601 Pen A and Pen B, AZP-3601, CALCIUM ARROW 500 mg, comprimé à sucer, AZP-3601, UN-ALFA 0,50 microgramme, capsule molle, ROCALTROL 0,25 microgramme, capsule molle

    Alexion Europe SAS

    Hypoparathyroidism

    phase 3 small molecule active

    1 trial

  19. Placebo for BHV-7000, Placebo BHV-7000, BHV-7000, BHV-7000

    Biohaven Bioscience Ireland Limited

    Refractory Focal Onset Epilepsy

    phase 3 small molecule active

    1 trial

  20. Placebo for BMS-936558, OPDIVO 10 mg/mL concentrate for solution for infusion.

    Bristol-Myers Squibb Australia Pty Ltd

    Subjects with resected adenocarcinoma or squamous cell carcinoma esophageal or gastroesophageal junction cancer

    phase 3 small molecule active

    1 trial

  21. Placebo for Belimumab Solution for Injection, 200 mg/mL, Benlysta 200 mg solution for injection in pre-filled syringe.

    GlaxoSmithKline

    systemic sclerosis associated interstitial lung disease

    phase 3 small molecule active

    1 trial

  22. Placebo for Benralizumab, Fasenra 30 mg solution for injection in pre-filled syringe, Symbicort forte Turbuhaler 320 microgramos/9 microgramos/inhalación polvo para inhalación., Symbicort Turbuhaler 160 microgramos/4,5 microgramos/inhalación polvo para inhalación

    AstraZeneca AB

    Eosinophilic Asthma

    phase 3 small molecule active

    1 trial

  23. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

  24. Placebo for Bepirovirsen Solution for Injection 150 mg/mL

    GlaxoSmithKline

    Hepatitis B, Chronic

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources